Display options
Cite
Wolbrette D. Antiarrhythmic Drugs: Age, Race, and Gender Effects. Card Electrophysiol Clin. 2010;2(3):369-378doi: 10.1016/j.ccep.2010.06.007.
Wolbrette, D. (2010). Antiarrhythmic Drugs: Age, Race, and Gender Effects. Cardiac electrophysiology clinics, 2(3), 369-378. https://doi.org/10.1016/j.ccep.2010.06.007
Wolbrette, Deborah. "Antiarrhythmic Drugs: Age, Race, and Gender Effects." Cardiac electrophysiology clinics vol. 2,3 (2010): 369-378. doi: https://doi.org/10.1016/j.ccep.2010.06.007
Wolbrette D. Antiarrhythmic Drugs: Age, Race, and Gender Effects. Card Electrophysiol Clin. 2010 Sep;2(3):369-378. doi: 10.1016/j.ccep.2010.06.007. PMID: 28770796.
Copy Download .nbib Format: NLM
Share it on

Card Electrophysiol Clin. 2010 Sep;2(3):369-378. doi: 10.1016/j.ccep.2010.06.007.

Antiarrhythmic Drugs: Age, Race, and Gender Effects.

Cardiac electrophysiology clinics

Deborah Wolbrette

Affiliations

  1. Penn State Heart & Vascular Institute, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, 500 University Drive, PO Box 850, MC H047, Hershey, PA 17033, USA.

PMID: 28770796 DOI: 10.1016/j.ccep.2010.06.007

Abstract

Women have a higher risk of developing torsade de pointes when taking QT-prolonging antiarrhythmic drugs. Elderly women with heart failure may have the highest risk of proarrhythmia. Greater caution should be used when treating women with these drugs, especially when additional risk factors for developing proarrhythmia are present. Women with congenital heart disease frequently experience arrhythmias during pregnancy, and use of antiarrhythmic drugs in this setting poses a special challenge. In the elderly population, the risk of antiarrhythmic drug use may outweigh the benefit, especially in individuals with asymptomatic arrhythmias. Limited data suggest potential ethnic differences in arrhythmic substrates and in proarrhythmic response to antiarrhythmic drugs.

Copyright © 2010 Elsevier Inc. All rights reserved.

Publication Types